Eledon 
Welcome,         Profile    Billing    Logout  
 2 Products   5 Diseases  2 Products   5 Trials   129 News 
6 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
tegoprubart (AT-1501) / Eledon
NCT04819880: Multicenter, Randomized, Open-Label Study to Evaluate AT-1501 in Patients Undergoing Kidney Transplant

Not yet recruiting
2
120
NA
AT-1501, Tacrolimus + mycophenolate
Eledon Pharmaceuticals
Kidney Transplant
09/22
03/25
NCT06126380: Long-Term Safety and Efficacy of Tegoprubart in Kidney Transplant Recipients

Enrolling by invitation
2
132
Europe, Canada, US, RoW
AT-1501, Tegoprubart, Tacrolimus
Eledon Pharmaceuticals
Kidney Transplant Rejection
12/29
12/29
NCT05125068 / 2021-004795-34: Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN)

Terminated
2
24
Europe, RoW
AT-1501
Eledon Pharmaceuticals
IgA Nephropathy, IgAN
07/23
07/23
AT-1501-K207, NCT05983770: Safety and Efficacy of Tegoprubart in Patients Undergoing Kidney Transplantation

Recruiting
2
120
Europe, Canada, US, RoW
AT-1501, Tegoprubart, Tacrolimus
Eledon Pharmaceuticals
Kidney Transplant Rejection
03/25
03/25
NCT06305286: Safety, Tolerability, and Efficacy of Immunomodulation With A Monoclonal Antibody Against CD40L in Combination With Transplanted Islet Cells in Adults With Brittle Type 1 Diabetes Mellitus (T1D)

Recruiting
1/2
3
US
AT-1501
University of Chicago, Juvenile Diabetes Research Foundation, Cure Alliance
Diabetes Mellitus
03/29
03/29
AT-1501-K102, NCT05027906: Safety, Pharmacokinetics, and Efficacy of AT 1501 in Patients Undergoing Kidney Transplant

Recruiting
1/2
24
Europe, Canada, RoW
AT-1501
Eledon Pharmaceuticals
Kidney Transplant
09/25
09/25

Download Options